Impacto de los psicofármacos en la piel: reacciones adversas y su manejo. Revisión sistemática

Julieta Ruiz Beguerie; Berenice Fouces

doi:10.47196/da.v31i3.2961

Authors

Julieta Ruiz Beguerie Austral University Hospital, Buenos Aires Province, Argentina
Berenice Fouces Austral University Hospital, Buenos Aires Province, Argentina

DOI:

https://doi.org/10.47196/da.v31i3.2961

Keywords:

psychotropic drugs, psychopharmaceuticals, adverse effects, adverse reaction, drug-related side effects, dermatology

Abstract

Psychopharmacological drugs represent a significant advancement in treating psychiatric conditions, yet their use carries the risk of adverse skin reactions (ASR). These reactions can vary from mild and self-limiting mucocutaneous symptoms to severe and life-threatening conditions. Our understanding of these adverse effects encompasses both immunological and non-immunological mechanisms. In this systematic review, we explore characteristics of ASRs associated with psychopharmacological drugs, along with recommendations for their management. While rash and pruritus are among the most common manifestations, these drugs can also trigger a spectrum of dermatological conditions, including Stevens-Johnson syndrome. It is important to cautiously interpret a skin reaction as a consequence of a specific psychotropic drug in the context of mental health treatment, as discontinuing it without confirmation of its association may pose risks to the stability of psychiatric treatment. Dermatologists play a crucial role in the multidisciplinary care of these patients, offering expertise in the diagnosis and treatment of ASRs. Their involvement ensures comprehensive and effective management, ultimately enhancing the well-being of individuals receiving psychopharmacological treatment for mental health disorders.

Author Biographies

Julieta Ruiz Beguerie, Austral University Hospital, Buenos Aires Province, Argentina

Dermatologist, Dermatology Service

Berenice Fouces, Austral University Hospital, Buenos Aires Province, Argentina

Chief Dermatology Resident, Dermatology Department

References

I. Kristensen KB, Pedersen SA, Schmidt SAJ, Pottegård A. Use of antiepileptic drugs and risk of skin cancer. A nationwide case-control study. J Am Acad Dermatol. 2020;82:326-335

II. Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, et ál. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry. 2009;70:1258-1265.

III. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief. 2011:1-8

IV. Wang F, Zhao Y-K, Li M, Zhu Z, et ál. Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study. Cutan Ocul Toxicol. 2017;36:370-376.

V. Deb N, Dey D, Roy P. Psychotropic medications and dermatological side effects: an in-depth review. Psychoactives. 2024:3:22-24.

VI. Edinoff AN, Nguyen LH, Fitz-Gerald MJ, Crane E, et ál. Lamotrigine and Stevens-Johnson syndrome prevention. Psychopharmacol Bull. 2021;51:96-114.

VII. Xu YY, Sun ZL, Zhang XL, Liu ZL, et ál. Carbamazepine induced Stevens-Johnson syndrome in Han Chinese with positive HLA-A * 3101 gene: a case report. Beijing Da Xue Xue Bao. 2023;55:755-757.

VIII. Bolaños-Rosales DM, Xajil-Ramos LY, González-Salazar LS. Medicamentos inductores a reacciones cutáneas severas reportados en países de Iberoamérica. Revisión. Rev Ofil Ilaphar. 2023;33:174-181.

IX. Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry. 1999;60:714-725.

X. Common terminology criteria for adverse events v3.0 (CTCAE). En: Principles and Practice of Clinical Trial Medicine. Elsevier 2008;461-533.

XI. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, et ál. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:119-142.

XII. Allain H, Chevrant-Breton J, Beneton C, Bousser AM, et ál. Conséquences dermatologiques indésirables des médicaments. Résultat d’une enquête de pharmacovigilance. Ann Med Interne. 1983;134:530-536.

XIII. Hernández RJM, Hierro S, Achell L. Patogenia del prurito en pacientes psiquiátricos. Revisión de la bibliografía y reporte de un caso. Dermatología CMQ. 2010;8:128-135.

XIV. Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin. 1996;14:503-508.

XV. Lozzi F, Di Raimondo C, Lanna C, Diluvio L, et ál. Latest evidence regarding the effects of photosensitive drugs on the skin. Pathogenetic mechanisms and clinical manifestations. Pharmaceutics. 2020;12:1104.

XVI. Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry. 2000;12:35-42.

XVII. Kass J, Hsu S. What is your diagnosis? Hyperpigmentation due to long-term chlorpromazine use. Cutis. 2001;68:252-260.

XVIII. Mishra B, Praharaj SK, Prakash R, Sinha VK. Aripiprazole-induced acneiform eruption. Gen Hosp Psychiatry. 2008;30:479-481.

XIX. Aksoy I, Orum M. Haloperidol decanoate-induced acneiform eruption: a case report. Med Sci. 2018:707.

XX. Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Expert Rev Dermatol. 2013;8:681-692.

XXI. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48:1223-1244.

XXII. Bloom R, Amber KT. Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. An Bras Dermatol. 2017;92:139-141.

XXIII. Alvarado M, Villamonte DS, Araúz C. Reporte de un caso clínico y revisión: síndrome de Stevens Johnson por uso de Lamotrigina. Pediátr Panama. 2018;3:29-36.

XXIV. Deshmukh RP. Olanzapine-induced reversible skin eruption. Indian J Psychiatry. 2023;65:607-609.

XXV. Naisbitt DJ, Farrell J, Wong G, Depta JPH, et ál. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393-1403.

XXVI. Mullins E, Guajardo N, Fuenzalida M, Clavero F. Reacciones cutáneas adversas a anticonvulsivantes y estabilizadores del ánimo. Rev Chil Dermatol. 2011;27:71-76.

XXVII. Schneck J, Fagot J-P, Sekula P, Sassolas B, et ál. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis. A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40.

XXVIII. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.e1-14; quiz 706-8.

XXIX. Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, et ál. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry. 2009;70:1258-1265.

XXX. Schmid S, Kuechler PC, Britschgi M, Steiner UC, et ál. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol. 2002;161:2079-2086.

XXXI. Jakhar J, Badyal R, Kumar S, Prasad S. Olanzapine-induced acute generalized exanthematous pustulosis: a case report. Indian J Psychiatry. 2021;63:411-413.

XXXII. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, et ál. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60-68.

XXXIII. Gupta MA, Gupta AK, Haberman HF. The self-inflicted dermatoses: a critical review. Gen Hosp Psychiatry. 1987;9:45-52.

XXXIV. Joly P, Janela B, Tetart F, Rogez S, et ál. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol. 2012;148:543-544.

XXXV. Moreno M, Wielandt AM, Encina G, Ortiz L. Farmacogenética en psiquiatría: estudio de variantes alélicas del CYP450 en pacientes chilenos con patología psiquiátrica. Rev médica Clin Las Condes. 2022;33:58-67.